Min Zhong,
Wang Shen,
Kenneth J Barr,
Jennifer P Arbitrario,
Michelle R Arkin,
Minna Bui,
Teresa Chen,
Brian C Cunningham,
Marc J Evanchik,
Emily J Hanan, [......],
Chris E Lawrence,
Jose R Martell,
Johan D Oslob,
Kumar Paulvannan,
Saileta Prabhu,
Jeffrey A Silverman,
Jasmin Wright,
Chul H Yu,
Jiang Zhu, W Mike Flanagan
[show abstract]
[hide abstract]
ABSTRACT: This letter describes the discovery of a novel series of tetrahydroisoquinoline (THIQ)-derived small molecules that potently inhibit both human T-cell migration and super-antigen induced T-cell activation through disruption of the binding of integrin LFA-1 to its receptor, ICAM-1. In addition to excellent in vitro potency, 6q shows good pharmacokinetic properties and its ethyl ester (6t) demonstrates good oral bioavailability in both mouse and rat. Either intravenous administration of 6q or oral administration of its ethyl ester (6t) produced a significant reduction of neutrophil migration in a thioglycollate-induced murine peritonitis model.
Bioorganic & medicinal chemistry letters 09/2010; 20(17):5269-73. · 2.65 Impact Factor